GlassScriptPhysician profile
Mozhgan Zafar
NPI 1407053044
$3,012.04
in general payments reported to CMS, 2019-2025
31 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $261 · 2021: $480 · 2022: $360 · 2023: $485 · 2024: $317 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.68 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.35 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $349.80 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.39 | 2019-2024 | Ofev, Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $251.31 | 2021-2023 | |
| Amgen INC. | $229.22 | 2019-2024 | Repatha |
| Lilly USA, LLC | $210.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $153.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $140.20 | 2019-2025 | Dupixent |
| Exact Sciences Corporation | $101.71 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $100.84 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $82.00 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $77.39 | 2019-2023 | Shingrix |
| Abbvie INC. | $74.60 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $56.64 | 2019-2021 | |
| Dexcom, INC. | $55.24 | 2021-2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $54.50 | 2022-2023 | Nexletol, Nexlizet, Contrave |
| Esperion Therapeutics, INC. | $44.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.17 | 2020-2024 | Xifaxan |
| Genzyme Corporation | $33.52 | 2025 | |
| Corcept Therapeutics | $32.65 | 2019 | |
| Baxter Healthcare | $30.99 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Nevro Corp. | $19.40 | 2024 | Senza |
| Endo Pharmaceuticals INC. | $18.26 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.78 | 2023 | Quviviq |
| Genentech USA, INC. | $16.63 | 2019 | |
| Horizon Therapeutics Plc | $14.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.37 | 2019 | |
| Eisai INC. | $14.27 | 2021 | |
| Insmed, INC. | $13.90 | 2024 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $12.56 | 2021 | |
| Merck Sharp & Dohme LLC | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mozhgan Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.